Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial
作者： D. Cella , A.S. Pickard , M.S. Duh , A. Guerin , N. Mishagina
DOI: 10.1016/J.EJCA.2011.05.017
关键词: Surgery 、 Clinical trial 、 Internal medicine 、 Placebo 、 Pazopanib 、 Confidence interval 、 Hazard ratio 、 Quality of life 、 Medicine 、 Randomized controlled trial 、 Progressive disease
摘要: … This analysis extends the Sternberg et al. findings of the original analysis which compared the magnitude of average changes in HRQoL between the treatment arms at each specific …
elsevier.com
sci-hub.se 参考文章(14)
D Osoba, G Rodrigues, J Myles, B Zee, J Pater, Interpreting the significance of changes in health-related quality-of-life scores. Journal of Clinical Oncology. ,vol. 16, pp. 139- 144 ,(1998) , 10.1200/JCO.1998.16.1.139
Ronald Bukowski, David Cella, Kathleen Gondek, Bernard Escudier, None, Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer. American Journal of Clinical Oncology. ,vol. 30, pp. 220- 227 ,(2007) , 10.1097/01.COC.0000258732.80710.05
Paul Dolan, Modeling Valuations for EuroQol Health States Medical Care. ,vol. 35, pp. 1095- 1108 ,(1997) , 10.1097/00005650-199711000-00002
David Cella, Quality of life in patients with metastatic renal cell carcinoma: The importance of patient-reported outcomes Cancer Treatment Reviews. ,vol. 35, pp. 733- 737 ,(2009) , 10.1016/J.CTRV.2009.07.003
David Cella, Jim Z. Li, Joseph C. Cappelleri, Andrew Bushmakin, Claudie Charbonneau, Sindy T. Kim, Isan Chen, Robert J. Motzer, Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial Journal of Clinical Oncology. ,vol. 26, pp. 3763- 3769 ,(2008) , 10.1200/JCO.2007.13.5145
A Simon Pickard, Maureen P Neary, David Cella, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer Health and Quality of Life Outcomes. ,vol. 5, pp. 70- 70 ,(2007) , 10.1186/1477-7525-5-70
Robert J Motzer, Bernard Escudier, Stéphane Oudard, Thomas E Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A Thompson, Robert A Figlin, Norbert Hollaender, Gladys Urbanowitz, William J Berg, Andrea Kay, David Lebwohl, Alain Ravaud, None, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial The Lancet. ,vol. 372, pp. 449- 456 ,(2008) , 10.1016/S0140-6736(08)61039-9
John S. Lam, Alberto Breda, Arie S. Belldegrun, Robert A. Figlin, Evolving Principles of Surgical Management and Prognostic Factors for Outcome in Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 5565- 5575 ,(2006) , 10.1200/JCO.2006.08.1794
Fairooz F. Kabbinavar, Joel F. Wallace, Eric Holmgren, Jing Yi, David Cella, Kathleen J. Yost, Herbert I. Hurwitz, Health-Related Quality of Life Impact of Bevacizumab When Combined with Irinotecan, 5-Fluorouracil, and Leucovorin or 5-Fluorouracil and Leucovorin for Metastatic Colorectal Cancer Oncologist. ,vol. 13, pp. 1021- 1029 ,(2008) , 10.1634/THEONCOLOGIST.2008-0003
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Olivier Rixe, Stéphane Oudard, Sylvie Negrier, Cezary Szczylik, Sindy T. Kim, Isan Chen, Paul W. Bycott, Charles M. Baum, Robert A. Figlin, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. The New England Journal of Medicine. ,vol. 356, pp. 115- 124 ,(2007) , 10.1056/NEJMOA065044